These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 12942097)

  • 1. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors.
    Yamasaki S; Henzan H; Ohno Y; Yamanaka T; Iino T; Itou Y; Kuroiwa M; Maeda M; Kawano N; Kinukawa N; Miyamoto T; Nagafuji K; Shimoda K; Inaba S; Hayashi S; Taniguchi S; Shibuya T; Gondo H; Otsuka T; Harada M;
    Bone Marrow Transplant; 2003 Sep; 32(5):505-10. PubMed ID: 12942097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone.
    Devine SM; Brown RA; Mathews V; Trinkaus K; Khoury H; Adkins D; Vij R; Sempek D; Graubert T; Tomasson M; Goodnough LT; DiPersio JF
    Bone Marrow Transplant; 2005 Sep; 36(6):531-8. PubMed ID: 16025152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.
    Cao TM; Wong RM; Sheehan K; Laport GG; Stockerl-Goldstein KE; Johnston LJ; Shizuru JA; Negrin RS; Lowsky R
    Exp Hematol; 2005 Mar; 33(3):279-85. PubMed ID: 15730851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
    Zhao XY; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
    Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model.
    Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L
    Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.
    Remberger M; Naseh N; Aschan J; Barkholt L; LeBlanc K; Svennberg P; Ringdén O
    Bone Marrow Transplant; 2003 Jul; 32(2):217-23. PubMed ID: 12838288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR; Mayani H
    Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
    Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors.
    Kim DH; Sohn SK; Lee NY; Baek JH; Kim JG; Won DI; Suh JS; Lee KB; Shin IH
    Eur J Haematol; 2005 Oct; 75(4):299-308. PubMed ID: 16146536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies.
    Chang YJ; Zhao XY; Huang XJ
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):323-34. PubMed ID: 18275899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
    Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
    Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic peripheral blood stem cell transplantation from two- or three-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies.
    Yamasaki S; Ohno Y; Taniguchi S; Yoshida T; Hayashi S; Ogawa H; Shimazaki C; Takahashi S; Kasai M; Wake A; Nishimura M; Tokunaga K; Gondo H; Takaue Y; Harada M; Mineishi S;
    Bone Marrow Transplant; 2004 Feb; 33(3):279-89. PubMed ID: 14647250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases.
    Sohn SK; Kim DH; Kim JG; Sung WJ; Baek JH; Lee NY; Won DI; Suh JS; Lee KS; Lee KB
    Eur J Haematol; 2004 Jun; 72(6):430-6. PubMed ID: 15128422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
    Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
    Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
    Bensinger WI; Martin PJ; Storer B; Clift R; Forman SJ; Negrin R; Kashyap A; Flowers ME; Lilleby K; Chauncey TR; Storb R; Appelbaum FR
    N Engl J Med; 2001 Jan; 344(3):175-81. PubMed ID: 11172139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation.
    Mohty M; Bilger K; Jourdan E; Kuentz M; Michallet M; Bourhis JH; Milpied N; Sutton L; Jouet JP; Attal M; Bordigoni P; Cahn JY; Sadoun A; Ifrah N; Guyotat D; Faucher C; Fegueux N; Reiffers J; Maraninchi D; Blaise D
    Leukemia; 2003 May; 17(5):869-75. PubMed ID: 12750699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
    Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
    Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.